First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study-Reference-Cited by-同舟云学术

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Published:2015-09 Issue:9 Volume:26 Page:1883-1889
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wu Y.-L.,Zhou C.,Liam C.-K.,Wu G.,Liu X.,Zhong Z.,Lu S.,Cheng Y.,Han B.,Chen L.,Huang C.,Qin S.,Zhu Y.,Pan H.,Liang H.,Li E.,Jiang G.,How S.H.,Fernando M.C.L.,Zhang Y.,Xia F.,Zuo Y.

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/9/1883/16701310/mdv270.pdf

Reference18 articles.

1. Cancer statistics 2013;Siegel;CA Cancer J Clin,2013

2. EGFR through STAT3 modulates ΔN63&agr; expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas;Ripamonti;J Cell Physiol,2013

3. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009